Lutonix BTK IDE: First Level 1 evidence of positive safety and efficacy for DCB below the knee


Patrick Geraghty (St Louis, USA) presented new datapoints from the six-month outcomes of the Lutonix BTK IDE trial at the 2018 VEITHsymposium (13–17 November, New York, USA). In addition to the positive safety and efficacy data that were presented at the VIVA 2018 meeting, the new data presented at VEITHsymposium showed statistical difference between the six-month primary patency (a combined endpoint of total occlusion and clinically-driven target lesion revascularisation [CD-TLR]) obtained in the drug-coated balloon (DCB) arm when compared to that obtained in the standard balloon angioplasty arm. Further, there were no gender differences in terms of outcome for both the safety and efficacy primary endpoints in the DCB arm. The trial enrolled patients in North America, the European Union and Japan.

This video was sponsored by BD.


Please enter your comment!
Please enter your name here